Centene (CNC) Stock May Be Below Fair Value On Raised Outlook

Centene stock has almost doubled over the past year, yet on broad valuation checks it still screens as relatively cheap compared with its own fundamentals and sector peers. For anyone tracking managed care, the question is whether a strong share price run has already captured the improvement story or whether the current multiple still leaves some room in the tank.

• Centene shares are up 91.9% over the past year, which puts recent enthusiasm well ahead of the stock’s longer term track record.
• Recent progress on profitability and a renewed push on data and AI under a new CIO can support earnings quality, while shrinking enrollment in key segments remains a risk for how dependable those cash flows look.
• On Simply Wall St’s composite checks, Centene earns a high value score of 5 out of 6, which means the stock leans undervalued across most of the valuation yardsticks used.

The issue now is whether Centene’s current price still offers an attractive entry point relative to what these valuation markers suggest.

Scan beyond Centene and identify other health insurers that still screen as relatively inexpensive on fundamentals with our curated 33 high quality undervalued stocks.

Is Centene Still Cheap on Sales?

P/S works well for Centene because investors often focus on how efficiently it turns large premium volumes into sustainable profit.

On this lens, the stock trades at a P/S of 0.2x, far below the Healthcare industry average of 1.4x and below the peer group near 1.7x. The Fair Ratio model, which blends factors such as margins, size and sector risk, points to a P/S of about 1.0x as a reasonable anchor. That comparison suggests the current revenue multiple is well under the level indicated by this framework for a managed care business with Centene’s profile.

Despite the strong Q2 print and higher full year EPS guidance lifting sentiment around Centene, the valuation still assigns a discounted price tag to each dollar of sales. The stock appears inexpensive on a P/S basis relative to both its tailored Fair Ratio and the broader health insurance group.

See what the numbers say about this price — find out in our valuation breakdown.

The Centene Narrative: What Would Justify Today's Price?

Simply Wall St Narratives for Centene pick up where the valuation puzzle leaves off and explain what sort of growth, margin profile and earnings path would need to occur for the stock to be worth materially more or less than today’s price, based on different scenarios discussed on the Community page. Rather than relying on a single multiple or model, each scenario lays out its own assumptions so you can later compare them with Centene's reported numbers.

Community views on Centene sit far apart, with one camp focused on Medicaid and Marketplace repair and the other on policy and contract risk.

Bull case: 9% undervalued

"Overall strength and competitiveness in winning Medicaid contracts, such as the fully integrated D-SNP in Illinois and Medicaid expansion into rural Nevada, may drive future revenue growth and market share..."

Read the full Bull Case to see why Centene could be undervalued

Bear case: 16% overvalued

"Rising government scrutiny over managed care costs and ongoing legislative focus on pricing transparency are set to intensify regulatory pressure on Centene, increasing the risk of lower reimbursement rates and margin compression across Medicaid and Marketplace lines..."

Read the full Bear Case to see why Centene could be overvalued

Do you think there's more to the story for Centene? Head over to our Community to see what others are saying!

The Bottom Line

Centene still screens as undervalued on market multiples, even after a strong 1 year return, which keeps the valuation debate very much alive. The core question is whether profitability and contract execution can stay solid enough for that discount to close, or whether shrinking enrollment and policy risk justify it sticking around. For investors tracking the stock, the key issue is whether current margins and earnings quality prove durable enough that the market eventually relaxes its caution, or if the lower multiple is simply fair compensation for the ongoing regulatory and reimbursement uncertainty.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com